Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy have?
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy has 172 citations in the OpenAlex counts ScholarIQ stores.
When was Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy published?
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy has 2020 year in the ScholarIQ index.
What is the open-access status of Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy?
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy has gold oa status in the ScholarIQ index.
What is the DOI of Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy?
The DOI for Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy is on the source record.
What is the PMID of Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy?
The PMID for Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy is on the source record.
What is the OpenAlex record for Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy?
The OpenAlex for Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy is on the source record.